Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Bray

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Cell|July 18, 2006
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesisKurt Degenhardt, Robin Mathew, Brian Beaudoin, et al.
Cell|June 16, 2009
Autophagy suppresses tumorigenesis through elimination of p62Robin Mathew, Cristina M Karp, Brian Beaudoin, et al.
Plos One|August 1, 2012
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibitionKevin Bray, Robin Mathew, Alexandria Lau, et al.
Blood Advances|March 2, 2021
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cellsDavid J DiLillo, Kara Olson, Katja Mohrs, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2015
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacyChristina H Eng, Zuncai Wang, Diane Tkach, et al.
Clinical & Translational Immunology|February 9, 2022
Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma modelsKevin P Nishimoto, Taylor Barca, Aruna Azameera, et al.
Scientific Reports|July 14, 2021
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuningLauric Haber, Kara Olson, Marcus P Kelly, et al.
Science Translational Medicine|March 26, 2025
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivoRobert Salzler, David J DiLillo, Kei Saotome, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Cell|July 18, 2006
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesisKurt Degenhardt, Robin Mathew, Brian Beaudoin, et al.
Cell|June 16, 2009
Autophagy suppresses tumorigenesis through elimination of p62Robin Mathew, Cristina M Karp, Brian Beaudoin, et al.
Plos One|August 1, 2012
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibitionKevin Bray, Robin Mathew, Alexandria Lau, et al.
Blood Advances|March 2, 2021
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cellsDavid J DiLillo, Kara Olson, Katja Mohrs, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2015
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacyChristina H Eng, Zuncai Wang, Diane Tkach, et al.
Clinical & Translational Immunology|February 9, 2022
Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma modelsKevin P Nishimoto, Taylor Barca, Aruna Azameera, et al.
Scientific Reports|July 14, 2021
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuningLauric Haber, Kara Olson, Marcus P Kelly, et al.
Science Translational Medicine|March 26, 2025
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivoRobert Salzler, David J DiLillo, Kei Saotome, et al.
Pageof 2